Topic

Sarepta Therapeutics

3 stories related to this topic, newest first.

Regenxbio Gene Therapy for Duchenne Muscular Dystrophy Succeeds in Trial

Stat

science38 days ago

Regenxbio Gene Therapy for Duchenne Muscular Dystrophy Succeeds in Trial

Regenxbio announced on May 14, 2026 that its experimental treatment produced high levels of a miniaturized muscle protein, clearing the path for an FDA submission. The Rockville, Md.-based company aims to offer a safer and more effective option than Sarepta Therapeutics’ Elevidys…

1 source

Roche to Run New Elevidys Trial for European Approval; FDA Plans Advisory Panels on Compounded Peptides

Substrate placeholder — needs review

science52 days ago

Roche to Run New Elevidys Trial for European Approval; FDA Plans Advisory Panels on Compounded Peptides

Roche announced a new trial of Elevidys, Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy, to pursue approval in Europe. Meanwhile, the FDA will hold advisory panel meetings starting July 2026 to reconsider restrictions on compounded peptides.

1 source

Elevidys Gene Therapy Shows Positive Results in Duchenne Muscular Dystrophy Trial

Substrate placeholder — needs review

science74 days ago

Elevidys Gene Therapy Shows Positive Results in Duchenne Muscular Dystrophy Trial

Sarepta Therapeutics reported positive topline results from a phase 3 trial of its gene therapy Elevidys for Duchenne muscular dystrophy. The trial met its primary endpoint of improved motor function in patients aged 4 to 7. The Duchenne muscular dystrophy field has experienced s…

1 source